These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26248511)

  • 1. Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort.
    Ledgerwood JE
    Lancet Infect Dis; 2015 Oct; 15(10):1117-1119. PubMed ID: 26248511
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
    Juan-Giner A; Tchaton M; Jemmy JP; Soumah A; Boum Y; Faga EM; Cisse M; Grais RF
    Vaccine; 2019 Nov; 37(48):7171-7177. PubMed ID: 30266489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
    Huttner A; Siegrist CA
    Expert Rev Vaccines; 2018 Dec; 17(12):1105-1110. PubMed ID: 30422031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
    Medaglini D; Siegrist CA
    Curr Opin Virol; 2017 Apr; 23():88-94. PubMed ID: 28460340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.
    Farooq F; Beck K; Paolino KM; Phillips R; Waters NC; Regules JA; Bergmann-Leitner ES
    Sci Rep; 2016 Jun; 6():27944. PubMed ID: 27323685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Misinterpretation of Ebola Virus PCR Results After rVSV ZEBOV-GP Vaccination.
    Cnops L; Gerard M; Vandenberg O; Van den Wijngaert S; Heyndrickx L; Willems E; Demeulemeester K; De Clerck H; Dediste A; Callens S; De Munter P; Vlieghe E; Bottieau E; Wuillaume F; Van Esbroeck M; Ariën KK
    Clin Infect Dis; 2015 Jun; 60(11):1725-6. PubMed ID: 25694650
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
    Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
    Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
    Huttner A; Agnandji ST; Combescure C; Fernandes JF; Bache EB; Kabwende L; Ndungu FM; Brosnahan J; Monath TP; Lemaître B; Grillet S; Botto M; Engler O; Portmann J; Siegrist D; Bejon P; Silvera P; Kremsner P; Siegrist CA; ; ;
    Lancet Infect Dis; 2018 Jul; 18(7):738-748. PubMed ID: 29627147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
    Gsell PS; Camacho A; Kucharski AJ; Watson CH; Bagayoko A; Nadlaou SD; Dean NE; Diallo A; Diallo A; Honora DA; Doumbia M; Enwere G; Higgs ES; Mauget T; Mory D; Riveros X; Oumar FT; Fallah M; Toure A; Vicari AS; Longini IM; Edmunds WJ; Henao-Restrepo AM; Kieny MP; Kéïta S
    Lancet Infect Dis; 2017 Dec; 17(12):1276-1284. PubMed ID: 29033032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closer than ever to an Ebola virus vaccine.
    Banadyga L; Marzi A
    Expert Rev Vaccines; 2017 May; 16(5):401-402. PubMed ID: 28322076
    [No Abstract]   [Full Text] [Related]  

  • 15. Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study.
    Carnino L; Vetter P; Peyraud N; Aebischer-Perone S; Chappuis F; Huttner A; Kaiser L; Eperon G
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34128975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
    Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
    N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebola vaccines in clinical trial: The promising candidates.
    Wang Y; Li J; Hu Y; Liang Q; Wei M; Zhu F
    Hum Vaccin Immunother; 2017 Jan; 13(1):153-168. PubMed ID: 27764560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
    ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
    CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INFECTIOUS DISEASES. Unusual Ebola vaccine study pays off in Guinea.
    Enserink M
    Science; 2015 Aug; 349(6248):569-70. PubMed ID: 26250660
    [No Abstract]   [Full Text] [Related]  

  • 20. Global Advisory Committee on Vaccine Safety, 10-11 June 2015.
    Wkly Epidemiol Rec; 2015 Jul; 90(29):365-72. PubMed ID: 26189216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.